Patients with advanced stage breast carcinoma immunoreactive to biotinylated Herceptin® are most likely to benefit from trastuzumab-based therapy: an hypothesis-generating study
Titel:
Patients with advanced stage breast carcinoma immunoreactive to biotinylated Herceptin® are most likely to benefit from trastuzumab-based therapy: an hypothesis-generating study
Auteur:
Sapino, A. Montemurro, F. Marchiò, C. Viale, G. Kulka, J. Donadio, M. Bottini, A. Botti, G. dei Tos, A.P. Bersiga, A. Di Palma, S. Truini, M. Sanna, G. Aglietta, M. Bussolati, G.